Evidence map›Paper›PMID 36054098›Full record

ArticleJournal of the American Chemical Society2022

Development of a GalNAc-Tyrosine-Specific Monoclonal Antibody and Detection of Tyrosine

Li Xia, Tiffany R Bellomo, Ruslan Gibadullin, Molly D Congdon, Elijah F Edmondson, Mi Li, Alexander Wlodawer, Crystal Li, J Sebastian Temme, Pavan Patel and 2 more

Open access · greenAbstract read
In one paragraph

Article in Journal of the American Chemical Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Li XiaChemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702, United States.
Tiffany R BellomoChemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702, United States.
Ruslan GibadullinChemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702, United States.ORCID 0000-0001-8439-0218
Molly D CongdonChemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702, United States.
Elijah F EdmondsonMolecular Histopathology Laboratory, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702, United States.
Mi LiCenter for Structural Biology, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702, United States.
Alexander WlodawerCenter for Structural Biology, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702, United States.ORCID 0000-0002-5510-9703
Crystal LiChemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702, United States.
J Sebastian TemmeChemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702, United States.ORCID 0000-0001-8306-2810
Pavan PatelChemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702, United States.
Donna ButcherMolecular Histopathology Laboratory, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702, United States.
Jeffrey C GildersleeveChemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702, United States.ORCID 0000-0002-3744-6423
Frederick National Laboratory for Cancer Research · USLeidos (United States) · USNational Cancer Institute · US

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
Structural Basis of Immune Recognition of Glycosylated AntigensU54GM062116 · NIGMS · SCRIPPS RESEARCH INSTITUTE, THE · PI ALVAREZ, RICHARD · 2001 to 2010
$80.3M
Development of a Carbohydrate MicroarrayZIABC010675 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI GILDERSLEEVE, JEFFREY · 2009 to 2025
$6.1M
Intramural NIH HHS ZIA BC010675NCI NIH HHS 75N91019D00024NIGMS NIH HHS U54 GM062116
6 · The paper itself

Abstract

Glycosylation is a vital post-translational modification involved in a range of biological processes including protein folding, signaling, and cell-cell interactions. In 2011, a new type of

Indexed as

Antibodies, MonoclonalN-AcetylgalactosaminyltransferasesCell LineGlycosylationHumansTyrosineAntibodies, MonoclonalN-AcetylgalactosaminyltransferasesTyrosine

Identifiers

PMID36054098
PMCPMC10655760
OpenAlexW4294295640

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.